相关实验视频
Updated: Jul 28, 2026

07:47
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
概括
目前的证据不支持风险群体广泛接种肺炎球菌疫苗. 需要进一步的研究来确定受益于肺炎球菌多糖体疫苗的特定人群.
科学领域:
- 医学 医学 医学 医学 医学
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 肺炎球菌多糖体疫苗于1977年获得批准.
- 建议包括2岁以上的高风险人群,如50岁以上的慢性病患者或在机构中的患者.
研究的目的:
- 批判性地审查支持目前针对肺炎球菌疫苗接种的建议的证据.
- 确定肺炎球菌多糖体疫苗在不同人群中的有效性和必要性.
主要方法:
- 关于肺炎球菌疾病发病率和死亡率的现有证据的文献综述.
- 对不同风险群体的疫苗疗效的评估,包括慢性病患者,老年人和住院患者.
主要成果:
- 在推的高风险类别中,肺炎球菌疾病发病率或死亡率增加的有限文献.
- 没有令人信服的证据表明疫苗对慢性病患者的有效性,除了患有状细胞疾病的儿童.
- 尚未发表的研究表明,对门诊,老年人或住院患者没有益处.
结论:
- 目前的数据不支持在美国广泛的肺炎球菌疫苗接种.
- 需要进行进一步的调查,以确定肺炎球菌多糖体疫苗有益的具体情况.
更多相关视频
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
相关概念视频
Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...